Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The histone deacetylase 8 (histone deacetylase like 1 or HDAC8 or EC 3.5.1.98) targeted pipeline therapeutics report provides comprehensive information on the histone deacetylase 8 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in histone deacetylase 8 targeted therapeutics development with respective active and dormant or discontinued projects.
What are the key molecule type in the histone deacetylase 8 pipeline market?
The key molecule type in the histone deacetylase 8 pipeline market are small molecule and synthetic peptide. Small molecule has the highest number of products in the histone deacetylase 8 pipeline market.
Histone deacetylase 8 pipeline market, by molecule type
For more molecule type insights, download a free sample
What are the key companies in the histone deacetylase 8 pipeline market?
The key companies in the histone deacetylase 8 pipeline market are Jubilant Therapeutics Inc, Medibiofarma SL, NatureWise Biotech & Medicals Corp, Oceanyx Pharmaceuticals Inc, Shuttle Pharmaceuticals Inc, and Zhejiang Hisun Pharmaceutical Co Ltd.
key companies in the histone deacetylase 8 pipeline market
To know about more key companies, download a free sample
Market report overview
Key molecule type | Small Molecule and Synthetic Peptide |
Key companies | Jubilant Therapeutics Inc, Medibiofarma SL, NatureWise Biotech & Medicals Corp, Oceanyx Pharmaceuticals Inc, Shuttle Pharmaceuticals Inc, and Zhejiang Hisun Pharmaceutical Co Ltd |
Scope
- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Medibiofarma SL
NatureWise Biotech & Medicals Corp
Oceanyx Pharmaceuticals Inc
Shuttle Pharmaceuticals Inc
Zhejiang Hisun Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key molecule type in the histone deacetylase 8 pipeline market?
Small molecule and synthetic peptide are the key molecule type in the histone deacetylase 8 pipeline market.
-
What are the key companies in the histone deacetylase 8 pipeline market?
Jubilant Therapeutics Inc, Medibiofarma SL, NatureWise Biotech & Medicals Corp, Oceanyx Pharmaceuticals Inc, Shuttle Pharmaceuticals Inc, and Zhejiang Hisun Pharmaceutical Co Ltd are the key companies in the histone deacetylase 8 pipeline market.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.